wada prohibited list cjc-1295 ipamorelin Peptide Regulation News: FDA Updates,

References: Ionescu M, Frohman LA

J Vet Pharmacol Ther 40:140147

Introduction Peptide therapies have rapidly entered mainstream musculoskeletal culture, driven by social media promotion, direct-to-consumer wellness and optimization clinics, and the expanding commercialization of biologic optimization (Vasireddi et al

The CJC-1295 + Ipamorelin blend is listed at BergdorfBio as a research substance and is intended exclusively for laboratory purposes

With a 30-minute half-life on the CJC-1295 (No DAC) side, spacing the two several hours apart means the GHRH signal has largely cleared before the ghrelin signal is working and the supra-additive effect is what you lose

These studies are cited, and the researchers claims are explained below